The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Ezra Y. Rosen(Memorial Sloan Kettering Cancer Center), Alexander Drilon(Memorial Sloan Kettering Cancer Center)

Nature Communications

March 18, 2022

10.1038/s41467-022-28848-x

Cited by 110

Related Papers

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

|Nature Medicine|2023|100

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

|Cancer Discovery|2023|65

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

|Cancer Discovery|2024|45